Answers are grounded in this paper and cite their sources.
SUMMARYHuman pathogenic viruses, including HIV, hepatitis B virus, and hepatitis C virus, as well as recent global outbreaks and pandemics caused by RNA viruses such as severe acute respiratory syndrome coronavirus (SARS-CoV; 2002-2003), Middle East respiratory syndrome-CoV (2012-2015 and 2019), and SARS-CoV-2 (2019-2023), have resulted in a significant loss of life. The development of antiviral drugs has provided therapeutic options, enabling more effective treatment. With the discovery of idoxuridine, the first antiviral nucleoside approved by the U.S. Food and Drug Administration in 1963, a series of antiviral nucleosides and nucleotides has been approved worldwide over the following 60 years. These drugs, with the potential to interfere with DNA/RNA synthesis, demonstrated unique therapeutic mechanisms. In this review, we focus on adenine nucleoside and nucleotide analogs as antiviral drugs, summarizing their antiviral mechanisms across the viral life cycle, representative potent small-molecule agents with diverse scaffolds, current clinical development, and combination therapies, as well as modification strategies based on the adenosine scaffold developed over the past 60 years. In addition to the development of new antiviral agents, some adenine nucleoside and nucleotide analogs have been repurposed for new indications, and some of them, such as remdesivir, exhibit broad-spectrum antiviral activity. Through the summary of past achievements, current challenges, and available opportunities in both biology and chemistry, we hope to inspire the future development of antiviral nucleosides/nucleotides.
No takes yet. Share an insight, caveat, or question.
Bi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: